Pancreatic cancer is the 12th most common cancer worldwide but the 4th leading cause of cancer-death in developed countries. In the United States in 2016, approximately 53,070 people were expected to develop pancreatic cancer, and 41,780 of those cases were expected to succumb to the disease.
The current standard of care for patients with nonresectable pancreatic cancer (stage 3 or 4) includes FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and 5-FU) or a combination of gemcitabine and nab-paclitaxel. These treatments are often poorly tolerated. FOLFIRINOX is associated with a high rate of Grade 3-4 (serious) adverse events, can rarely be administered for more than six months, and is mostly prescribed to patients with excellent performance status.